U.S. Stem Cell, Inc. (USRM)
| Market Cap | 662.00 -99.0% |
| Revenue (ttm) | 82.05K -59.1% |
| Net Income | -2.86M |
| EPS | -0.00 |
| Shares Out | 661.51M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 50,000 |
| Open | 0.000001 |
| Previous Close | 0.0001 |
| Day's Range | 0.000001 - 0.000001 |
| 52-Week Range | n/a |
| Beta | -99.89 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 28, 2026 |
About U.S. Stem Cell
U.S. Stem Cell, Inc. engages in the research, development, and commercialization of stem cell and regenerative treatments in the United States and internationally. The company develops MyoCell, an autologous muscle stem cell therapy which is preparing for phase II/III clinical trials for the treatment of heart damage in heart failure patients; MyoCell SDF-1, an autologous cell therapy which completed the IND application for the treatment of chronic damage in the heart and enhancement of blood vessel formation; and AdipoCell, a clinical protocol... [Read more]
News
Mark Borman Appointed Chairman of the Board of USRM
SUNRISE, FL / ACCESSWIRE / March 9, 2022 / U.S. Stem Cell, Inc. (OTC PINK:USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutio...
What do U.S. Stem Cell’s Risk Factors Tell Investors?
Biotechnology company U.S. Stem Cell, Inc. (USRM) is focused on bringing to market autologous cellular therapies to treat heart damage, and vascular and autoimmune diseases. Its business is focused on...